Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation
Authors:
- Donald W. MacGlashanDonald W. MacGlashan
- Sarbjit S. SainiSSSarbjit S. Saini
- 1 October 2013
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 132 (4) , 906-911.e4
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AI070345)
- National Institutes of Health (AI070345)
This publication has 40 references indexed in Scilit:
- Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthmaClinical & Experimental Allergy, 2011
- Shaping the response: the role of Fc∊RI and Syk expression levels in mast cell signallingIET Systems Biology, 2010
- Regulation of Syk kinase and FcRβ expression in human basophils during treatment with omalizumabJournal of Allergy and Clinical Immunology, 2010
- Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challengeJournal of Allergy and Clinical Immunology, 2010
- Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophilsJournal of Leukocyte Biology, 2009
- The size of the disease relevant IgE antibody fraction in relation to ‘total‐IgE’ predicts the efficacy of anti‐IgE (Xolair®) treatmentAllergy, 2009
- CD‐sens: a biological measure of immunological changes stimulated by ASITAllergy, 2009
- Basophil Histamine Release Decreases during Omalizumab Therapy in Allergic AsthmaticsInternational Archives of Allergy and Immunology, 2007
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Enhanced basophil histamine release to concanavalin A in allergic rhinitisJournal of Allergy and Clinical Immunology, 1986